Pfizer on Monday said it would buy weight loss drugmaker Metsera in an up to $7.3 billion deal, including future payments, as it scrambles to win a slice in the booming obesity drug market. Pfizer said it will pay an initial$47.50 a share in cash for Metsera, a nearly 43% premium to the biotech company's Friday's closing price of $33.32. That gives the deal an enterprise value of$4.9 billion. The pact also includes a contingent value right worth up to $22.50 a share based on potential clinical and regulat ...